These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 31081696)

  • 21. Acute myeloid leukemia targets for bispecific antibodies.
    Hoseini SS; Cheung NK
    Blood Cancer J; 2017 Feb; 7(2):e522. PubMed ID: 28157217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells.
    Urbanska K; Lynn RC; Stashwick C; Thakur A; Lum LG; Powell DJ
    J Transl Med; 2014 Dec; 12():347. PubMed ID: 25496493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap.
    Longhitano AP; Slavin MA; Harrison SJ; Teh BW
    Blood Rev; 2021 Sep; 49():100810. PubMed ID: 33676765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cancer therapy using bispecific antibodies].
    Kadowaki N
    Rinsho Ketsueki; 2018; 59(10):1942-1947. PubMed ID: 30305495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.
    Reusch U; Harrington KH; Gudgeon CJ; Fucek I; Ellwanger K; Weichel M; Knackmuss SH; Zhukovsky EA; Fox JA; Kunkel LA; Guenot J; Walter RB
    Clin Cancer Res; 2016 Dec; 22(23):5829-5838. PubMed ID: 27189165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
    Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
    Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement.
    Long M; Mims AS; Li Z
    Immunol Invest; 2022 Nov; 51(8):2176-2214. PubMed ID: 36259611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies.
    Hoseini SS; Espinosa-Cotton M; Guo HF; Cheung NV
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33239418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. "NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results.
    Thakur A; Lum LG
    Expert Opin Biol Ther; 2016; 16(5):675-88. PubMed ID: 26848610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting.
    Li X; Zhang P; Sun H; Han L; Jiang Z; Yu J
    Expert Opin Biol Ther; 2023; 23(12):1193-1195. PubMed ID: 37852928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.
    Leong SR; Sukumaran S; Hristopoulos M; Totpal K; Stainton S; Lu E; Wong A; Tam L; Newman R; Vuillemenot BR; Ellerman D; Gu C; Mathieu M; Dennis MS; Nguyen A; Zheng B; Zhang C; Lee G; Chu YW; Prell RA; Lin K; Laing ST; Polson AG
    Blood; 2017 Feb; 129(5):609-618. PubMed ID: 27908880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances.
    Yu L; Wang J
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):941-956. PubMed ID: 30798356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blinatumomab for the treatment of B-cell lymphoma.
    Oak E; Bartlett NL
    Expert Opin Investig Drugs; 2015 May; 24(5):715-24. PubMed ID: 25739952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?
    Rashidi A; Walter RB
    Expert Rev Hematol; 2016; 9(4):335-50. PubMed ID: 26778118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells.
    Kuo SR; Wong L; Liu JS
    Protein Eng Des Sel; 2012 Oct; 25(10):561-9. PubMed ID: 22740616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
    Goebeler ME; Bargou R
    Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Recent progress of bispecific antibody-based therapy for hematological malignancies].
    Ochi T
    Rinsho Ketsueki; 2022; 63(9):1298-1309. PubMed ID: 36198556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The potential role of Bi-specific antibodies in acute myeloid leukemia.
    Yilmaz M; Ravandi F
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101218. PubMed ID: 33279174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances of bispecific antibodies in solid tumors.
    Yu S; Li A; Liu Q; Yuan X; Xu H; Jiao D; Pestell RG; Han X; Wu K
    J Hematol Oncol; 2017 Sep; 10(1):155. PubMed ID: 28931402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-Redirected Bispecific Antibodies.
    Lussana F; Gritti G; Rambaldi A
    J Clin Oncol; 2021 Feb; 39(5):444-455. PubMed ID: 33434063
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.